论文部分内容阅读
目的:探讨硫酸镁微量气泵吸入治疗2岁以内小儿毛细支气管炎的临床效果。方法:选取毛细支气管炎患儿共86例,随机分为对照组42例和试验组44例。所有患儿均进行常规抗炎治疗,对照组静脉滴注硫酸镁,试验组用空气雾化泵微量气泵装置吸入硫酸镁,比较两组患儿治疗效果。结果:治疗后两组患儿的氧分压(PaO_2)和血氧饱和度(SaO_2)均升高,二氧化碳分压(Pa CO2)下降,且试验组改善更明显,差异有统计学意义(t_(PaO_2)=5.234,P<0.05;t_(SaO_2)=5.214,P<0.05;t_(PaCO_2)=5.326,P<0.05)。试验组总有效率高于对照组(χ~2=4.012,P<0.05),且总不良反应发生率低于对照组(χ~2=4.363,P<0.05)。试验组的临床症状控制(喘息消失、咳嗽控制、体温恢复正常及哮鸣音消失)时间(t=5.264,P<0.05)和住院时间短于对照组(t=5.623,P<0.05)。治疗3 d后试验组临床评分低于对照组,差异有统计学意义(t=6.231,P<0.05)。结论:采用硫酸镁微量气泵吸入治疗2岁以内小儿毛细支气管炎安全有效,且不良反应发生率低,值得临床推广应用。
Objective: To investigate the clinical effect of inhalation of magnesium sulfate micropump on infantile bronchiolitis within 2 years old. Methods: A total of 86 children with bronchiolitis were randomly divided into control group (n = 42) and experimental group (n = 44). All children were treated with conventional anti-inflammatory therapy. The control group received intravenous infusion of magnesium sulfate. The experimental group inhaled magnesium sulfate using an air atomization pump and micro-pump device. The therapeutic effect was compared between the two groups. Results: After treatment, both PaO_2 and SaO_2 were increased and PaCO 2 decreased, and the improvement in the experimental group was more obvious with significant difference (t_ (PaO_2) = 5.234, P <0.05; t SaO_2 = 5.214, P <0.05; PaCO_2 = 5.326, P <0.05). The total effective rate of the experimental group was higher than that of the control group (χ ~ 2 = 4.012, P <0.05), and the incidence of the total adverse reaction was lower than that of the control group (χ ~ 2 = 4.363, P <0.05). The clinical symptoms control (disappearance of wheeze, cough control, normal temperature recovery and disappearance of wheeze) in the experimental group were shorter than those in the control group (t = 5.264, P <0.05). After 3 days of treatment, the clinical scores of the experimental group were lower than those of the control group, with significant difference (t = 6.231, P <0.05). Conclusion: Magnesium sulfate micropump inhalation is safe and effective for children with bronchiolitis within 2 years, and the incidence of adverse reactions is low, which is worthy of clinical application.